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Abstract:  Spuma-  or  foamy  viruses  (FV),  endemic  in  most  non-human  primates,  cats, 
cattle and horses, comprise a special type of retrovirus that has developed a replication 
strategy combining features of both retroviruses and hepadnaviruses. Unique features of 
FVs include an apparent apathogenicity in natural hosts as well as zoonotically infected 
humans,  a  reverse  transcription  of  the  packaged  viral  RNA  genome  late  during  viral 
replication resulting in an infectious DNA genome in released FV particles and a special 
particle  release  strategy  depending  capsid  and  glycoprotein  coexpression  and  specific 
interaction between both components. In addition, particular features with respect to the 
integration profile into the host genomic DNA discriminate FV from orthoretroviruses. It 
appears  that  some  inherent  properties  of  FV  vectors  set  them  favorably  apart  from 
orthoretroviral vectors and ask for additional basic research on the viruses as well as on the 
application in Gene Therapy. This review will summarize the current knowledge of FV 
biology and the development as a gene transfer system. 
Keywords: Foamyviruses; retroviral vectors; LAD; Fanconi Anemia 
 
OPEN ACCESS Viruses 2011, 3                         
 
 
562 
1. Introduction  
Spuma- or foamy viruses (FVs) have co-evolved with their natural hosts and are endemic to most 
non-human primates, cats, cattle and horses [1,2]. Man is not a natural host for FVs but can be infected 
through zoonosis [3,4]. A hallmark of FVs is their apparent apathogenicity in natural hosts as well as 
in infected humans. This is in stark contrast to their highly cytopathic nature in vitro, where infection 
ultimately results in the death of most target cells due to syncytia formation and vacuolization. 
Research on FVs during the last two decades has revealed a very special replication strategy of 
these viruses, combining features of both retroviruses and hepadnaviruses [5]. As a result, a couple of 
years  ago the  family  of  retroviridae  was  reorganized  [6].  FVs  now  constitute the  single  genus  of 
spumaviruses  in  the  Spumaretrovirinae  subfamily  of  retroviruses  and  are  set  apart  from  all  other 
retroviral genera that make up the subfamily of the Orthoretrovirinae. 
The best-studied FV species is the Prototype FV (PFV), which for many years was known as human 
FV  (HFV).  It  was  first  described  in  the  early  70s  of  the  last  century  after  isolation  from  a 
nasopharyngal carcinoma from a Kenyan patient [7]. However, its high sequence homology to FVs 
from chimpanzee (SFVcpz) and the lack of evidence of ―natural‖ human infections strongly suggests 
that this virus is derived by a zoonotic transmission from a chimpanzee [8–11]. Such trans-species 
transmissions appear to occur commonly upon occupational of casual contact of men with non-human 
primates [4,12]. 
This review summarizes our current knowledge on the biology of FVs, concentrating predominantly 
on PFV as well as their development and application as a gene transfer tool. 
2. The FV Replication Cycle, an Overview 
To begin we shall give a brief overview of our current knowledge of the sequential steps of FV 
replication in vitro (Figure 1). FV infection starts with attachment to target cells and binding to an, as 
yet unknown, but potentially very ubiquitous cellular receptor(s). It is thought that most FV species 
enter target cells predominantly by receptor-mediated endocytosis and the FV glycoprotein-dependent 
release of intact capsids into the cytoplasm requires a pH-dependent fusion process [13]. Upon arrival 
of capsids into the cytoplasm, they seem to dock to dynein motor protein complexes and migrate along 
microtubules  towards  the  microtubule  organizing  center  (MTOC)  where  they  accumulate  [14].  In 
resting cells, FV capsids can be detected at the MTOC for very long periods and still remain infectious 
[15]. Further disassembly apparently involves capsid processing by viral and cellular proteases and 
appears to be cell cycle dependent [16–18]. Nuclear localization of the FV preintegration complex, 
whose  composition  has  not  been  characterized  in  detail,  seems  to  require  nuclear  membrane 
breakdown  [17,18].  A  tethering  of  FV  Gag  to  chromatin  by  a  specific  sequence  motif,  thereby 
enhancing  viral  integration,  has  been  suggested  [19].  Upon  establishment  of  the  proviral  state, 
expression  of  FV  genes  by  the  cellular  transcription  machinery  is  regulated  through  a  viral 
transactivator utilizing internal and LTR derived promoter elements [20]. Differentially spliced RNAs 
are exported out of the nucleus, some by a novel CRM1-dependent pathway [21]. FV Gag protein has 
recently been implicated to contribute to nuclear RNA export as well [22]. FV protein translation of 
accessory, capsid and enzymatic gene products takes place in the cytoplasm, whereas glycoproteins are Viruses 2011, 3                         
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translated  at  the  rough  endoplasmic  reticulum  (ER)  and  targeted  to  the  secretory  pathway.  FV 
glycoprotein  intracellular  transport  and  cell  surface  expression  are  negatively  regulated  by  an  ER 
retrieval signal and ubiquitination [23,24]. FVs follow a B/D morphotype retroviral assembly strategy 
involving  transport  of  Gag  to  the  MTOC  where  a  preassembly  of  capsids  takes  place.  Unlike 
orthoretroviruses,  FVs  reverse  transcribe  their  packaged  RNA  genome  after  capsid  assembly  in  
virus-producing cells and those particles containing full-length viral DNA (about 10–20% of total) 
contribute most to viral infectivity [25–27]. Furthermore, in an in vitro system a nuclear reshuttling 
and  reintegration  of  viral  genomes  in  producer  cells  was  observed  [28,29].  Budding  and  particle 
release  of  FVs  into  the  environment  is  strictly  Env-dependent,  since  FV  Gag  apparently  lacks  a 
membrane-targeting signal typically present in orthoretroviral capsid proteins [30,31]. Therefore, FVs 
are unable to release virus like particles (VLPs) in an orthoretroviral fashion. Virion budding of most 
FV  species  is  observed  predominantly  at  putative  intracellular  membranes  of  ill-defined  origin  
(e.g., ER, Golgi) but to a limited extent also at the plasma membrane. For release of particles from the 
infected cells FVs like other viruses exploit the cellular machinery of vacuolar protein sorting (Vps) 
[32,33].  Unlike  other  retroviral  glycoproteins  the  FV  Env  appears  to  contain  structural  functions 
involved in particle formation, which results in the additional release of capsidless subviral particles 
(SVPs) from FV infected cells, a process that is controlled by posttranslational modification of the 
glycoprotein [23,33,34]. 
Figure  1.  Schematic  overview  of  the  spuma-  or  foamy  viruses  (FV)  replication  cycle. 
Electron  micrographs  (courtesy  of  H.  Zentgraf  and  J.  Krijnse-Locker,  Heidelberg)  of 
different steps of FV particle morphogenesis are shown in the upper panel. 
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3. Genome Organization and Transcription 
The typical proviral genome of FVs resembles that of other complex retroviruses (Figure 2). In 
addition to the canonical open reading  frames (ORFs) encoding a group specific  antigen (Gag), a 
polymerase (Pol) and an envelope (Env) protein, flanked by long terminal repeats (LTRs), FVs contain 
at least two additional ORFs, one extending into the 3' LTR, that encode proteins with regulatory and 
immunomodulatory functions.  
Figure 2. Spuma- or foamy viruses (FV) RNA and DNA genomic organization. Schematic 
outline  of  the  FV  proviral  genome  (top)  and  the  genomic  (middle)  and  subgenomic 
transcripts  generated  by  cellular  RNA  polymerase  from  long  terminal  repeat  (LTR)  and 
internal  promoter  (IP).  c:  cap  structure;  An:  poly-alanine;  CAS:  cis-acting  sequence;  
PPT: poly purine tract: U3: LTR unique 3' region; R: LTR repeat region; U5: LTR unique 5' 
region; PR: protease domain; RT/RH: reverse transcriptase-RNAse H domain; IN: integrase 
domain; LP: leader peptide domain; SU: surface domain; TM: transmembrane domain. 
 
 
An unusual feature of FV proviral organization is the presence of an internal promoter (IP) within 
the env ORF, in addition to the typical retroviral promoter located in the U3 region of the 5' LTR [34]. 
The IP, which has a low basal activity, drives expression of the accessory genes [35,36]. One of these, 
Tas (trans-activator of spumaviruses), is a potent transcriptional activator [37,38]. The details of FV 
transcription regulation have still to be worked out but it is known that Tas binds to specific sequences Viruses 2011, 3                         
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upstream of the IP [39,40]. Through a positive feedback loop Tas thereby increases its own expression. 
Further accumulation of Tas subsequently leads also to trans-activation of the FV LTR promoter by 
recognition of specific sequence motifs in the U3 region, resulting in transcription of the FV structural 
genes and genomic RNA [20,39,40]. In comparison to the IP, binding of Tas to the LTR U3 region 
appears to occur with  lower affinity, but higher avidity  [20,39,40]. In the absence of Tas, the U3 
promoter  is  virtually  transcriptional  inactive  [38].  By  this  mechanism  FVs  appear  to  regulate  the 
balance  between  early  and  late  protein  expression  [21].  However,  with  the  probable  exception  of 
bovine  FV  (BFV)  [41–43],  the  contribution  of  cellular  factors  and  their  interaction  with  the  FV 
transactivator Tas is largely unknown. 
The second, more abundant protein translated from mRNAs originating predominantly from the IP 
is Bet [44,45]. For a long time no essential function could be attributed to this protein for  in vitro 
replication  of  FVs  [46].  It  is  only  in  recent  years  that  a  function  for  Bet  has  evolved  as  a  viral 
antagonist for the host cells’ innate defense system, by neutralization of cellular APOBEC3 protein 
functions [47–49]. 
As a retrovirus FV faces the problem of nuclear export of differentially spliced RNAs. Complex 
orthoretroviruses express accessory proteins that facilitate export of unspliced and partially spliced 
viral RNAs by recognition of specific RNA secondary structure elements. For example, the HIV-1 Rev 
binds within these viral transcripts linking them to the CRM1-dependent cellular RNA export pathway 
[50,51].  No  such  function  has  been  reported  for  any  of  the  FV  accessory  proteins.  In  contrast, 
unspliced transcripts of simple orthoretroviruses appear to harbor specific RNA structural elements 
(CTE, constitutive transport elements) that directly feed the respective viral RNAs into the cellular 
NXF1/NXT1  RNA  export  machinery  [52,53].  A  very  recent  report  suggests  that  FVs  utilize  yet 
another mechanism, a mixture of both orthoretroviral export strategies. Export of unspliced and single 
spliced  FV  structural  protein  encoding  mRNAs  appears  dependent  on  the  CRM1-dependent  RNA 
export machinery. However, unlike other complex retroviruses crosslinking to CRM1 is mediated by 
additional  cellular  proteins  and  not,  as  in  the  case  of  orthoretroviruses,  by  a  viral  protein  [21]. 
Sequence elements within the FV RNAs essential for nuclear export still await their characterization. 
In addition, a potential role of FV Gag in viral RNA export has been proposed recently, based on a 
putative nuclear export signal (NES) in the N-terminal domain of the protein [22]. 
Another feature distinguishing FVs from orthoretroviruses is the expression of Pol from a separate 
singly spliced RNA [54–56]. Thus, FVs unlike all other retroviruses express no Gag-Pol fusion protein 
[57]. This raises a couple of important questions on the FV replication strategy. Firstly, how do they 
control the balance between capsid and polymerase protein translation that appears to be critical for 
proper capsid assembly and virion infectivity of orthoretroviruses? It was reported that cellular FV Pol 
levels are regulated by an inefficient Pol splice acceptor site located in the gag ORF [58]. In addition, 
FVs seem to tolerate greater differences in the ratios of Gag and Pol proteins than orthoretroviruses, 
since in-frame Gag-Pol fusion proteins still support the generation of infectious FV particles, whereas 
in the case of orthoretroviruses this abolishes infectious virus production [59]. Secondly, this unusual 
Pol biosynthesis as an independent protein also necessitates a Pol particle incorporation mechanism 
that is different from that of orthoretroviruses. In the case of FVs the full-length viral genomic RNA 
seems  to  bridge  Gag  and  Pol  proteins  during  assembly,  as  RNA  and  Pol  incorporation  requires 
recognition of specific regions within the virus genome by Gag and Pol [60–62]. However, additional Viruses 2011, 3                         
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protein-protein interactions of both proteins were reported to be required for Pol particle incorporation 
as  well  [63].  Interestingly,  only  the  Pol  precursor  protein,  but  not  the  mature  cleavage  products, 
appears to be efficiently packaged into assembling FV particles [62,64]. 
4. FV Structural Proteins 
The genome of FVs encodes the canonical gag, pol and env retroviral structural genes. However, 
their  biosynthesis  and  functions  deviate  significantly  in  several  aspects  from  their  orthoretroviral 
homologues and are summarized here (Figure 3). 
Figure  3.  The  spuma-  or  foamy  viruses  (FV)  structural  gene  products.  Schematic  of 
domain organization of Prototype FV (PFV) Gag (A), PFV Pol (B), and PFV Env (C).  
(D) Proposed membrane topology and oligomeric organization of PFV Env. (E) Schematic 
outline of a PFV particle. CC: coiled-coil motif; L: PSAP late-assembly (L)-domain motif; 
A:  YXXLGL  assembly  domain  motif;  GR:  glycine-arginine  rich  box;  PR:  protease 
domain; RT: reverse transcriptase domain; RH: RNAse H domain; IN: integrase domain;  
h: hydrophobic domain of the leader peptide (LP); FP: fusion peptide of the transmembrane 
subunit  (TM);  MSD:  membrane-spanning  domain  of  the  TM  subunit;  N:  N-terminus;  
C: C-terminus. 
 Viruses 2011, 3                         
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5. FV Gag 
Like all retroviruses, FVs translate a Gag precursor protein that is encoded by the full-length or 
(pre-) genomic viral RNA. In the case of PFV, this is a protein of 71 kD in size. Efficient FV Gag 
translation requires an upstream splice donor (SD) site, but not necessarily the original FV SD within 
the LTR R region [65,66]. Unlike orthoretroviruses the FV Gag undergoes only a limited proteolytic 
cleavage upon maturation [67]. The typical orthoretroviral processing products matrix (MA), capsid 
(CA), and nucleocapsid (NC) are not observed during FV Gag biosynthesis. During capsid assembly 
the FV Gag precursor (PFV p71
Gag) gets cleaved only once near the C-terminus resulting in a larger 
(PFV  p68
Gag)  and  a  smaller  (PFV  p3
Gag)  cleavage  product.  The  viral  capsid  is  composed  of  the 
precursor protein and the larger cleavage product at a ratio of 1:1 to 1:4 [68]. Gag precursor cleavage is 
essential  for  infectivity  but  not  particle  release,  since  particles  containing  only  Gag  precursor  are 
exported  but  are  non-infectious  and  show  incompletely  closed  capsids  in  ultrastructural  analysis 
[69,70]. By contrast, particles containing only the larger cleavage product and no precursor display a 
particle morphology and pattern of release that are indistinguishable from those of the wild type but 
are about 100-fold less infectious [69]. Some reports suggest that further FV Gag processing by the 
viral  and  cellular  proteases occurs  upon target  cell  entry  and  is  essential  for  productive  infection, 
probably by controlling capsid disassembly [16,71]. 
Several functional domains or motifs have been characterized within the FV Gag protein, although 
it does not display the typical orthoretroviral MA, CA, and NC subdomain structure. In the first place, 
PFV Gag harbors four predicted coil-coil (CC) domains  [72]. The most N-terminal domain (CC1) 
seems to be involved in Gag-Env interactions that are essential for particle release (see below). The 
second  coiled-coil  domain  (CC2)  is  reported  to  provide  Gag-Gag  interaction  essential  for  capsid 
assembly [73]. It is suggested that the third (CC3) mediates interaction with light chains of dynein 
motor protein complexes that apparently are exploited by FVs for transport of incoming particles to the 
MTOC [14]. No function has been assigned to the fourth coiled-coiled domain (CC4). Secondly, a 
motif with strong homology to the B/D morphotype of retroviruses cytoplasmic targeting and retention 
signal (CTRS) is thought to be responsible for Gag transport to the MTOC where preassembly of 
newly  generated  FV  capsid  takes  place  [74–76].  However,  unlike  Mason-Pfizer  monkey  virus 
(MPMV), where specific  mutations  in the CTRS lead to a conversion  from a B/D-type towards a  
C-type capsid assembly strategy, all currently examined FV CTRS mutations abolish capsid assembly 
completely and result in a nuclear accumulation of the mutant proteins [77]. Thirdly, like many other 
viruses FV exploit the cellular Vps machinery, in particular the ESCRT protein complexes, during the 
late stages of particle release to completely pinch-off from cellular membranes. Therefore, FV Gag 
proteins  harbor  an  L-domain  [32,33].  Experimentally  L-domain  function  has  so  far  only  been 
confirmed for PFV Gag and it has been shown that interaction of a PSAP L-domain motif with cellular 
TSG101 (a component of ESCRT-I) is essential for efficient particle release [33]. Interestingly, only 
the primate FV Gag proteins contain PSAP L-domain motifs, suggesting that they all use TSG101 and 
ESCRT-I for pinch-off. However, the fact that non-primate FVs lack this type of L-domain raises the 
question  as  to  whether  they  utilize  the  Vps  machinery  as  well,  potentially  by  linking  Gag  to the 
ESCRT machinery through other L-domain motifs. Fourthly, a conserved YXXLGL motif close to 
CC4 appears to have a function  in proper capsid assembly  by  influencing capsid  morphology and Viruses 2011, 3                         
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thereby the efficiency of intraparticular reverse transcription similar as the C-terminal domain (CTD) 
of the CA subunit of HIV (see below) [78]. Fifthly, FV Gag proteins lack the typical Cys-His motifs of 
orthoretroviral  Gag  proteins  with  implicated  function  in  different  steps  of  retroviral  replication 
including genome packaging [79]. Instead, the C-terminus of the larger Gag processing product in all 
FV species is rich in glycine (G) and arginine (R) residues [80]. In primate FVs these are clustered in 
three GR-rich boxes (GR-boxes) and are thought to play roles in viral replication similar to those of the 
orthoretroviral Cys-His boxes [81]. GRI was originally thought to be essential for nucleic acid binding, 
but  two  studies  failed  to  confirm  this  and  suggested  functions  in  Pol  encapsidation  or  capsid 
morphology and reverse transcription [81,82]. An NLS function was initially attributed to GRII being 
responsible for the transient nuclear targeting of Gag during certain time points of PFV infection [80]. 
However, the requirement of the NLS for PFV replication, has been questioned and, furthermore, some 
non-primate  FV  Gag  proteins  fail  to  localize  to  the  nucleus  [54,83].  The  GRII  harbors  a  
chromatin-binding site (CBS) that was proposed to tether incoming capsid to chromatin by histone 
interactions and facilitate integration [19]. Finally, there may a role for GRII in intra-particular reverse 
transcription, thereby influencing infectivity of released PFV particles [81]. Furthermore, GRIII, the 
function of which is not known, may have a similar role in intraparticular reverse transcription [81]. 
Other peculiarities of FV Gag, such as the highly unusual rareness in lysine residues, were highlighted 
recently [72,84]. Quite recently a putative NES signal  in the N-terminal domain of PFV Gag was 
reported [22]. Based on this a similar function in nuclear export of unspliced or single spliced viral 
RNAs was proposed, as described for RSV Gag. However, this data awaits further confirmation. 
6. FV Pol 
Biosynthesis of FV Pol is unusual because of its translation as an independent precursor protein 
(PFV p127
Pol) from a separate mRNA and because of its special encapsidation strategy (see above). In 
addition FV Pol precursor maturation is different from orthoretroviruses. FV Pol is autocatalytically 
processed  into  only  two  subunits,  a  larger  one  (PFV  p85
PR-RT-RN)  with  protease  (PR),  reverse 
transcriptase  (RT)  and  RNAseH  (RN)  enzymatic  activities  and  a  smaller  one  (PFV  p40
IN)  with 
integrase activity. This is in contrast to the standard orthoretroviral processing into PR, RT and IN 
subunits [67]. Staining of FV infected cells with specific monoclonal antibodies indicated a nuclear 
localization of both FV Pol molecules [85]. However, a putative NLS signal has only been described 
for the FV IN subunit [86]. 
In terms of its biochemical properties FV RT appears to be more active and characterized by higher 
processivity than, for example, HIV-1 RT, while the in vitro fidelity appears to be similar [87–90]. Cell 
culture experiments, however, showed an unprecedented high fidelity of FV reverse transcription [91].  
Retroviral PRs are only active in a dimeric state, which raises the question of how FV PR activity is 
regulated. Interestingly, recombinant PFV and SFV PR-RT domains are predominantly monomeric in 
solution,  but  appear  to  have  some  proteolytic  activity  that  is  enhanced  by  high  salt  conditions 
[87,92,93]. One publication suggests that recombinant FV PR is able to form transient dimers and 
therefore escapes detection by traditional methods [92]. Another report proposed that PR dimerization 
and  activity  might  be  regulated  at the  precursor  protein  level  by  the  IN oligomerization  domains, 
favoring protein-protein interactions [94]. However, strong evidence has been provided in favor of the Viruses 2011, 3                         
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former by identifying a nucleic acid motif (PARM for protease-activating RNA motif) that is bound by 
the Pol precursor protein and regulates PR activity [95]. Thus, as with encapsidating Pol protein that 
activates  PR,  experimental  evidence  exists  for  both  dominating  protein-RNA  or  dominating  
protein-protein interactions and definite answers to these questions are still open. 
The FV IN subunit has attracted a lot of attention recently, as it was the first retroviral IN for which 
a crystal structure of the full-length subunit in complex with its viral substrate was obtained [96]. In 
contrast, for orthoretroviral IN subunits only subdomain structures could be solved so far, mainly as a 
result  of  the  poor  solubility  of  the  respective  recombinant  proteins.  The  availability  of  the  PFV 
intasome  structure, its susceptibility to HIV-1 IN strand transfer  inhibitors such as raltegravir and 
elvitegravir  and  its  enzymatic  efficiency  in  in  vitro  integration  assays  using  small  viral  DNA 
substrates, has opened up possibilities of revealing the key mechanism of retroviral integration and 
understanding the basics of IN inhibitor action [97–101]. 
7. FV Env 
The FV glycoprotein biosynthesis, like FV Pol, deviates significantly from that of other retroviral 
Env proteins. Like orthoretroviral glycoproteins, it is translated from a spliced mRNA to a precursor 
protein that is targeted by an N-terminal signal peptide (SP) to the rough ER and thereby inserted into 
the secretory pathway (Figure 1). However, in contrast to orthoretroviruses the FV SP is not cleaved 
co-translationally  by  the  cellular  signal  peptidase  complex.  Instead,  FV  Env  is  translated  as  a  
full-length precursor protein, with N-terminal attached SP (termed the leader peptide LP, because it is 
not a classical SP), central surface (SU) and C-terminal transmembrane (TM) domain, that initially 
adopts a type III membrane topology with both N- and C-terminus located in the cytoplasm (Figure 3 
C and D) [102,103]. FV Env precursor processing into LP (gp18
LP), SU (gp80
SU) and TM (gp48
TM) 
subunits occurs along its transport to the cell surface and is mediated by furin or furin-like proteases 
[104,105]. Proteolytic cleavage of SU and TM, but not LP and SU subunits,  is essential  for viral 
infectivity  [104].  The  protein  gets  heavily  N-glycosylated  at  14 out of  15  potential  sites  and  two 
evolutionary conserved sites, one in SU (N8) and one in TM (N13), are important for viral infectivity 
[106].  In  contrast  to  orthoretroviruses,  the  LP  subunit,  probably  embedded  in  tripartite  trimeric 
glycoprotein complexes, is an integral component of the released viral particle (Figure 3E) and plays 
important additional roles in the replication cycle of FVs (see below) [75,103,107]. 
Intracellular transport of primate FV Env protein appears to be regulated by two major signals. The 
first is a C-terminal KKXX dilysine motif that results in retrieval of most Env proteins from early 
Golgi compartments into the ER in the absence of coexpression of other FV structural proteins [23], 
though it is not essential for viral replication [108]. In addition, the N-terminal cytoplasmic domain of 
the LP subunit  is posttranslationally  modified by ubiquitination at 4 out of 5 lysine residues  [24]. 
Ubiquitination  is  not  essential  for  viral  particle  release,  but  seems  to  suppress  the  glycoproteins 
intrinsic activity to release SVPs, since an ubiquitination deficient mutant shows a more than 50-fold 
increase in SVP release [24,109]. Interestingly, the domain within Env that is mediating the specific 
and  essential  interaction  with  the  capsid  during  budding  also  resides  in  the  N-terminus  of  LP 
[103,107].  Two  evolutionary  conserved  tryptophane  residues  (W10,  W13)  are  essential  for  this Viruses 2011, 3                         
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interaction [102,103]. Due to this specific Gag-Env interaction, which cannot be complemented by any 
other heterologous viral glycoprotein, FV vectors currently cannot be pseudotyped [110]. 
Although  the  ubiquitous  cellular  receptor(s)  of  FVs  still  awaits  identification  a  rough 
characterization  of  the  receptor-binding-domain  (RBD)  within  the  PFV  Env  SU  subunit  was 
established, demonstrating that amino acid (aa) 225 to 396 and 484 to 555, including the conserved  
N-glycosylation site N8, are essential to form the RBD [104]. The FV Env protein is responsible for 
the extremely broad host range of the viruses. Even evolutionary very distant cells from species like 
reptiles or birds are permissive for FV Env-mediated vector transduction [111]. Only recently, two cell 
lines of fish and human origin that appear to be resistant to FV Env-assisted gene transfer and might 
serve as useful tools to identify the elusive cellular receptor(s) were identified [112]. 
8. FV Egress 
Many steps of assembly and morphogenesis of FV particles resemble those of typical B/D-type 
retroviruses, such as MPMV. These viruses transport their Gag protein translated in the cytoplasm to 
an intracellular capsid assembly site [79]. Budding of the pre-assembled capsid then takes place unlike 
C-type retroviruses that assemble their capsid at and bud  from cellular membranes simultaneously 
[79]. FV Gag is transported to the cellular centrosome in a microtubule-dependent manner involving a 
specific  Gag  CTRS  motif  [76].  Accumulation  of  naked  capsids  can  be  observed  in  ultrastructural 
analysis [76]. Unique amongst retroviruses are several features of the FV egress process. First, is the 
dependence of FV capsids on coexpression of the cognate Env protein for subsequent steps of viral 
particle release [110]. FV capsids lack a membrane targeting signal resulting in the failure of FVs to 
release VLPs in the absence of the glycoprotein and the accumulation of capsids at the MTOC not 
being  associated  with  cellular  membranes  [31,76].  FV  particle  egress  is  dependent  on  a  specific 
interaction between FV Gag and Env involving domains in the N-terminus of both proteins (Gag CC1 
and Env LP, see above)  [102,103]. This dependency on the specific  natural  interaction  has so  far 
prevented modification of the FV tropism by pseudotyping of FV vector particles with heterologous 
glycoproteins [110]. FV particles can be engineered to release VLPs in an Env-independent fashion by 
artificial  N-terminal  fusion  of  heterologous  membrane  targeting  signals  to  Gag  [74,84].  However, 
these constructs remain non-infectious upon coexpression of heterologous glycoproteins or even the 
cognate Env protein [74,84].  
Another unusual feature of FVs, at least in the primate FVs, is the cellular location of their budding, 
which seems to occur predominantly at intracellular membranes, but to a limited extent as well as at 
the plasma membrane. Early reports indicated a budding of FVs capsids into the ER, which fitted quite 
well with the later characterization of a C-terminal KKXX ER-retrieval signal in the FV Env protein of 
many  FV  species  [23,113].  However,  this  ER  retrieval  signal  proved  to  be  dispensable  for  viral 
replication  and  only  marginal  changes  in  the  location  of  budding  could  be  observed  [108]. 
Furthermore,  some  non-primate  FVs  like  EFV  or  FFV  naturally  lack  an  ER-retrieval  signal  and 
budding of EFV exclusively at the plasma membrane has been described [114,115]. The nature of the 
vacuolar  structures  with  prominent  FV  budding  structures  frequently  observed  in  primate  FV 
expressing adherent cells still awaits further characterization. Due to the high cytopathic effects of FVs 
in  vitro  and  the  associated  disturbance  of  intracellular  organization  this  apparently  intracellular Viruses 2011, 3                         
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budding compartment might potentially represent other organelles such as the Golgi or, potentially, 
plasma membrane invaginations. 
The  initiation of reverse transcription of the packaged viral RNA genome during or soon after 
capsid assembly in the virus-producing cell is another unique feature of FVs among retroviruses [25]. 
Up to 20% of the viral nucleic acids in extracellular FV particles represents DNA, whereas it has been 
reported to be below 0.001% for orthoretroviruses [26,27]. Intraparticular reverse transcription of the 
packaged viral RNA genome is not dependent on particle release, since reverse transcription is easily 
detectable  in  intracellular  accumulated  capsids  of  Env-deficient  viruses  [25].  In  contrast,  a  proper 
microenvironment such as regular capsid morphology and yet unidentified cellular requirements, are 
essential for this process [78,81]. Experiments with RT inhibitors have demonstrated that the infectious 
viral genome of FVs and  FV vectors is  mainly  DNA  [25,27]. However, there are indications that 
further reverse transcription takes place upon FV target cell entry in a classical orthoretroviral fashion 
that  might  contribute  to  productive  infection  under  certain  conditions  for  example  at  low  MOI 
[116,117]. In addition, the characterization of FV sequences from feces of wild chimpanzees revealed 
only RNA genomes and no virion DNA [118]. This may indicate that there are differences between the 
replicative  behavior  of  FV  in  cell  culture  and  in  vivo.  However,  it  is  neither  known  whether  the  
feces-associated  FV  represent  the  infectious  form  of  the  virus  nor  what  cells  in  the  body  these 
viruses produced.  
The feature of late reverse transcription in the FV replication cycle, resulting in potential infectious 
capsids  in  the  virus  producing  cell,  underlies  another  unique  retroviral  feature,  the  intracellular 
retrotransposition (IRT) of FV genomes within an infected cell. A reintegration of reverse transcribed 
FV genomes, reminiscent of hepadnavirus nuclear genome reshuttling, was reported [28]. However, 
the frequency of 5% reported for cells transfected with Env-deficient PFV vector constructs represents 
quite  an  artificial  condition,  since  it  leads  to  an  intracellular  accumulation  of  FV  capsids  [28,29]. 
Furthermore, not all FVs seem to share this feature, as IRT was not detectable for FFV-derived vectors 
[27]. Therefore it remains an open question as to whether IRT is an epiphenomenon of env-deleted 
PFV vectors and occurs upon natural FV infection. 
9. FV Entry 
Little is known about the FV entry process. As previously mentioned, FVs are characterized by 
having an extremely broad host range, but the potentially ubiquitously expressed FV receptor(s) still 
awaits  its  identification  [111].  Infection  studies  using  MLV  vectors  pseudotyped  with  FV 
glycoproteins, together with the use of lysosomotropic agents as well as cell-cell fusion assays have 
been exploited to examine early processes of FV entry post receptor binding  [13]. These analyses 
indicated  an  uptake of  FV  particles  by  endocytosis  and  showed that  FV  Env-mediated  membrane 
fusion is a pH-dependent process [13]. However, whereas most FV Env species examined (SFVmac, 
FFV,  BFV,  EFV)  show  a  strong  induction  of  glycoprotein  fusion  activity  at  low  pH,  the  PFV 
glycoprotein  has  quite  a  high  basal  fusion  activity  at  neutral  pH  [13].  Indeed,  recent  single  virus 
particle  tracking  studies  using  autofluorescent  protein-tagged  FV  particles  and  time-lapse  video 
microscopy support differential uptake routes for PFV and SFVmac [119].  Viruses 2011, 3                         
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Upon release  into the cytoplasm  FV capsids are transported on microtubules to the centrosome 
where  they  accumulate  as  intact  naked  capsids,  a  process  that  is  inhibited  by  the  microtubule 
depolimerizing drug Nocodazole [14]. It has been suggested that FV capsids hijack cellular dynein 
motor protein complexes for this process by a direct interaction of the Gag CC2 domain with the 
dynein  light  chain  8  [14].  In  G0  arrested  cells  accumulated  FV  capsids  and  viral  genomes  are 
detectable  at  the  MTOC  for  weeks,  without  any  apparent  indication  for  further  virus  uncoating 
processes to occur [15]. This is consistent with other studies on the cell-cycle requirements for FV 
vector transduction, indicating a similar efficiency of FV and HIV-1 vectors in transducing quiescent 
G0 serum-starved fibroblasts, that was superior to that of MLV vectors [15,18,120]. Only upon cell 
activation FV disassembly proceeds, resulting in a productive infection [15]. Additional processing of 
the FV Gag protein by the viral and cellular proteases was suggested to be essential for this process 
[15,16]. The cellular signals triggering these further uncoating steps remain unclear. For cells arrested 
in the G1/S phase of the cell cycle, a block in the FV replication cycle has also been reported [121]. In 
contrast to G0 arrested cells, in this case capsid uncoating upon arrival at the MTOC seems to proceed, 
as virus genome is detectable in the nucleus [121]. However, under these conditions viral transcription 
and  viral  DNA  integration  is  inhibited  preventing  a  productive  infection  [121].  Thus  FV  vectors 
require mitosis for proviral integration and transgene expression [122]. However, they are able to form 
quite stable transduction intermediates in quiescent cells that can persist in a functional state for very 
long time periods until the cells reenter the cell cycle.  
The integration site profile of different retroviruses has gained increasing interest in recent years as 
it contributes to their potential to cause cancer in clinical Gene Therapy trials [123,124]. Large-scale 
studies  on  FV  vector  integration  site  profile  revealed  that they  have  a  much  lower  preference  for 
transcription  start  sites  than  MLV  vectors,  which  preferentially  integrate  at  these  locations  [125]. 
Furthermore, whereas HIV-1 vectors have a preference for integration in transcribed genes this is not 
the case for FV vectors [126–128]. Thus FV vectors display a more favorable integration site profile 
than MLV or HIV-1 based vectors. An unusual feature of the FV integrase mediated insertion of the 
viral genome into the host cell genome is the differential terminal trimming of the linear viral DNA 
genome [129,130]. Unlike orthoretroviruses that remove usually two nucleotides from the termini of 
the linear episomal viral reverse transcript, FVs process only the U5 terminus of the 3' LTR whereas 
the U3 terminus of the 5' LTR remains untouched [129,130]. The function of this special mechanistic 
feature of FV integration is currently unclear. 
10. FV Vector Systems 
During the last 15 years vector systems primarily  based  on PFV, SFVmac and FFV have been 
developed that allow production of high titer vector supernatants and efficient transduction of a large 
variety of target cells [111]. Unlike orthoretroviral vectors, the organization of cis-acting sequences 
(CAS) required for RNA and Pol packaging is more complex [131–133]. 
The latest generations of PFV transfer vectors are of the self-inactivating-type with minimal CAS 
elements [61,65,134]. Vector genome transcription is driven by chimeric 5' LTRs having the U3 region 
replaced  by  the  strong  cytomegalovirus  (CMV)  immediate  early  promoter  [61,65,134].  FV  CAS 
elements essential for efficient gene transfer comprise three regions of the genome (Figures 2 and 4). Viruses 2011, 3                         
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CAS-I spans the 5' LTR R region up to the first 200 nucleotides of the original Gag ORF (Figure 2). It 
includes the primer binding site (PBS) just downstream of the 5' LTR U5 region that is complementary 
to  the  3'  end  of  tRNA
Lys1,2  used  by  PFV  for  initiation  of—strand  DNA  synthesis  during  reverse 
transcription  [135].  Mutations  have  been  introduced  into  CAS-I  to  inactivate  the  authentic  Gag 
translation  start,  thereby  preventing  expression  of  residual  C-terminally  truncated  Gag  peptide 
sequences [65]. CAS-II was originally identified to be about 2 kb in size and located in the 3' region of 
the pol ORF and including a central poly-purine tract (PPT) [131–133]. It has been further minimized 
and is composed of a discontinuous element of 1.2 kb in size harboring RNA packaging as well as 
proposed Pol encapsidation and central PPT sequences (Figure 2) [61,62]. Finally, CAS-III includes 
about 40 nucleotides upstream of the 3' LTR containing the 3' PPT, about 200 bp of the 5' end of its U3 
region and the complete R region (Figure 4). Although, the FV LTR promoter is virtually inactive in 
the absence of the viral transactivator Tas, for safety reasons the 3' LTRs in FV vectors have large 
deletions  in  the  U3  region  encompassing  viral  promoter  and  enhancer  elements  [65,134].  Since 
transgene expression in FV vectors is not driven by the viral LTR, as it is for example in some murine 
leukemia virus (MLV)-based vectors, a transgene expression cassette with heterologous promoter is 
used. Generally this is inserted between CAS-II and CAS-III [65]. 
Figure 4. Third generation Prototype FV (PFV) vector system. Schematic outline of the 
third  generation  (A)  transfer  vector  PV  and  (B)  packaging  expression  vectors  for  
codon-optimized  (co)  Gag  (PG),  coPol  (PP),  and  coEnv  (PE).  CMV:  cytomegalovirus 
immediate  early  promoter;  R:  LTR  repeat  region;  U5:  LTR  unique  5'  region;  ∆U3: 
enhancer-promoter deleted LTR unique 3' region; Prom: internal heterologous promoter; 
CAS: cis-acting sequence; SD: splice donor; SA: splice acceptor. 
 
 
State of the art FV packaging systems are composed of three separate expression vectors; one for 
the viral Gag protein, one for Pol and one for Env (Figure 4). Expression of the original gag ORF is 
strictly dependent on an upstream SD site of FV or heterologous origin [65]. The use of a spliced 
transcript for pol gene expression is also highly recommended. Instead env can be expressed from 
unspliced mRNAs, although expression levels by vectors containing an upstream intron tend to be Viruses 2011, 3                         
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significantly higher. Separate gag and pol expression vectors result in higher titers than constructs 
containing both overlapping ORFs and using the natural pol SA in the gag ORF for translation of Pol 
from  a  spliced  RNA  [65].  Quite  recently,  further  improvement  in  vector  titers  was  achieved  by 
expression-optimization of all packaging constructs [81], allowing production of vector supernatants 
with up to 1 × 10
7 ffU/mL by transient transfection without further concentration steps, provided that 
the relative amounts of the packaging plasmids have been adjusted properly [136]. 
11. Experimental FV Vector Applications 
FV  vectors  were  shown  to  be  an  efficient  gene  delivery  vehicle  for  different  scientific  and 
therapeutic approaches in a variety of different target cells. This includes their ability to transduce 
efficiently  neuronal progenitor cells or embryonic  stem cells [137,138]. However, the best-studied 
application of FV vectors is for gene transfer into hematopoietic stem cells (HSCs) of different origin 
[139–142]. For example, FV vectors have been demonstrated to transduce efficiently mouse HSCs that 
are capable of long-term repopulation after consecutive BM transplantation [141,143]. Furthermore, 
marking experiments of dog HSCs indicate that they have a similar gene transfer potential as HIV-1 
vectors [140,144]. Similarly, FV vectors have a proven potential for efficient transduction of human 
HSC in the xenogenic NOD/SCID mouse  model  [139,141]. A direct comparison with HIV-1- and 
MLV- based vectors revealed that they are capable of a similar, if not higher, gene transfer efficiency 
as HIV-1 vectors and are superior to MLV-based vectors [139]. More importantly, only very short  
ex vivo transduction protocols are required for efficient transduction by FV vectors, which is beneficial 
for the maintenance of the engraftment potential of the modified HSCs [139,143].  
FV were shown not only to enable efficient marker gene transfer, but also transfer of therapeutic 
genetic material. In a dog model for leukocyte deficiency, transduction of CD34+ BM cells with a 
correct copy of the CD18 gene followed by transplantation of these modified cells was able to cure the 
disease phenotype in several animals [145]. In these dogs a long-term stable multilineage marking of 
the hematopoietic system was observed. Similarly, in a mouse model of Fanconi anemia C a short-term 
transduction  of  HSC  from  Fancc  knock-out  mice  with  a  Fancc  transgene-expressing  FV  vector 
reversed their repopulation defect [143]. 
12. Pseudotyping of Orthoretroviral Vectors with FV Env 
While pseudotyping of unmodified FV capsids with other than FV glycoproteins  is not possible 
[110], the other way round, i.e., pseudotyping of orthoretroviral capsids with FV Env, works well 
[146].  Long  before the  particular topology  of  FV  Env  was  known  [103],  attempts  to  increase  the 
principle  possibility  of  pseudotyping  MLV-based  vectors  by  modifying  the  membrane-spanning-
domain of FV TM were undertaken, and led only to a moderate increase in performance of the former 
[147]. After the discovery of the special characteristics of FV Env, mutants could be generated that 
allowed for pseudotyping that was as good as, if not superior to, the widely used VSV-G, particularly 
in transducing HSCs [136,146]. Given the opportunity to concentrate vectors bearing the FV Env 
[148], this opens up completely new avenues in generating lentiviral (HIV-1) vectors, since the FV 
Env  appears  to  be  less  toxic  than  VSV-G  and  easier  to  handle  in  the  vector  production  process 
[136,149]. Viruses 2011, 3                         
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13. Safety of FV Vectors 
Besides  their  high  efficiency  in  transducing  certain  and—from  a  practical  point  of  view—
interesting primary cell populations, such as HSCs, investigations into the safety profile of FV vectors 
were of prime interest. One of the great advantages of these vectors consists in the fact that they were 
derived from probably evolutionary extremely old and genomically hardly changed wildtype viruses, 
which co-evolved with their respective hosts [1]. Upon natural, experimental or accidental infection—
including transmission to humans—these viruses have been shown to be apathogenic in contrast to 
MLV and HIV-1, which induce severe specific diseases [150]. A report on the induction of a subclinical 
condition in male cats upon FFV infection has, so far, only proved to be anecdotal [151]. 
The probability of generating replicating virus using modern retroviral vectors—be they derived 
from  gamma-,  lenti-  or  foamy  viruses—is  so  extremely  low,  that  it  can  be  ignored  here.  Severe 
side-effects from clinical Gene Therapy trials with retroviral vectors result mainly from two more or 
less inherent features of the wildtype virus, which are not that easy to alter.  
Feature  one:  Due  to  the  integration  profile  into  the  host  genome,  a  given  vector  may  lead  to 
anti-oncogene  inactivation  or  to  proto-oncogene  activation.  Generally,  the  former  is  regarded  less 
dangerous than the latter. Proto-oncogene activation is more likely if the integration of a retroviral 
vector with  its strong enhancers occurs in the vicinity of the cellular gene. However, far-reaching 
long-distance  effects  may  also  contribute.  In  this  respect  it  is  remarkable  that  the  follow-up  of 
individual cellular clones from the FV vector-mediated canine CD18 trial neither revealed malignant 
transformation nor clonal dominance (i.e., a proliferative in vivo advantage of certain cells), even when 
the vector integrated in the vicinity of growth-promoting genes [152]. This study was performed more 
than three years following the initial bone marrow transplantation that cured the animals. It remains to 
be seen whether particular features of the host, of the disease or the vector are responsible for this 
beneficial outcome. It may turn out that FV LTRs behave like natural insulators, even in their deleted 
form present in the vector genomes. With respect to the integration profile, FV vectors show a much 
more random integration than their gamma- and lentiviral relatives, although this is not completely 
random [126,128,145]. 
Feature two: The other mechanism by which an integrating vector may harm the host cell is by 
readthrough of transcripts generated by the vector into cellular proto-oncogenes. Here the strength of 
the  polyA  signal  in  the  3'  LTR  appears  to  play  a  crucial  role.  This  is  not  easy  to  determine 
experimentally, but a system has been devised recently and the analysis revealed the following order: 
gammaretroviruses << lentiviruses < foamy viruses [153]. Also in this respect it appears that FV vectors 
take up a unique position among retroviral vectors that warrant further investigation and exploitation. 
As  far  as  non-integrating  FV  vectors  in  generating  induced  pluripotent  stem-cells  (iPSC)  are 
concerned [154], only time will tell whether they really offer an advantage over other means of viral or 
non-viral gene transfer [155].  
14. Conclusions and Outlook  
Vectors derived from FV have some features with respect to efficiency and safety which make them 
at least as good as their orthoretroviral cousins. These features appear to be a direct consequence of the Viruses 2011, 3                         
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particular FV replication strategy. Therefore, the analysis of any aspect of this replication strategy will 
be beneficial to the improvement of current FV vector systems. In the light of what has been detailed 
above, CD18 deficiency and Fanconi anemia are probably the first human diseases for which a clinical 
trial using FV vectors will be performed.  
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